File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1586/ecp.09.19
- Scopus: eid_2-s2.0-70249140575
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: Treatment of multidrug-resistant and extensively drug-resistant tuberculosis: Current status and future prospects
Title | Treatment of multidrug-resistant and extensively drug-resistant tuberculosis: Current status and future prospects |
---|---|
Authors | |
Keywords | Drug Resistant Fluoroquinolone New Drugs Treatment Tuberculosis |
Issue Date | 2009 |
Publisher | Expert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/loi/ecp |
Citation | Expert Review Of Clinical Pharmacology, 2009, v. 2 n. 4, p. 405-421 How to Cite? |
Abstract | Drug resistance in Mycobacterium tuberculosis arises from the man-made selection of mutants that result from spontaneous chromosomal alterations. Preventing the development of drug-resistant TB through a good control program based on directly observed treatment, short-course, is of paramount importance. Established multidrug-resistant (MDR)-TB requires alternative specific chemotherapy, comprising drugs with higher cost and greater toxicity delivered on a programmatic basis. The development of new anti-TB drugs would help to prevent and treat MDR-TB. Notably, moxifloxacin and gatifloxacin are being tested for shortening treatment in Phase III trials, while three novel compounds, TMC-207, OPC-67683 and PA-824 are in Phase II studies for both drug-susceptible and drug-resistant disease. The roles of surgery and immunotherapy in the management of MDR-TB require further evaluation. The recent emergence of extensively drug-resistant TB poses a serious challenge to the global control of TB. In order to combat extensively drug-resistant TB, strengthening of directly observed treatment, short-course and drug-resistance programs, alongside other strategies, including the development of newer diagnostics and drugs, is mandatory. © 2009 Expert Reviews Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/157557 |
ISSN | 2023 Impact Factor: 3.6 2023 SCImago Journal Rankings: 0.990 |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tam, CM | en_US |
dc.contributor.author | Yew, WW | en_US |
dc.contributor.author | Yuen, KY | en_US |
dc.date.accessioned | 2012-08-08T08:51:14Z | - |
dc.date.available | 2012-08-08T08:51:14Z | - |
dc.date.issued | 2009 | en_US |
dc.identifier.citation | Expert Review Of Clinical Pharmacology, 2009, v. 2 n. 4, p. 405-421 | en_US |
dc.identifier.issn | 1751-2433 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/157557 | - |
dc.description.abstract | Drug resistance in Mycobacterium tuberculosis arises from the man-made selection of mutants that result from spontaneous chromosomal alterations. Preventing the development of drug-resistant TB through a good control program based on directly observed treatment, short-course, is of paramount importance. Established multidrug-resistant (MDR)-TB requires alternative specific chemotherapy, comprising drugs with higher cost and greater toxicity delivered on a programmatic basis. The development of new anti-TB drugs would help to prevent and treat MDR-TB. Notably, moxifloxacin and gatifloxacin are being tested for shortening treatment in Phase III trials, while three novel compounds, TMC-207, OPC-67683 and PA-824 are in Phase II studies for both drug-susceptible and drug-resistant disease. The roles of surgery and immunotherapy in the management of MDR-TB require further evaluation. The recent emergence of extensively drug-resistant TB poses a serious challenge to the global control of TB. In order to combat extensively drug-resistant TB, strengthening of directly observed treatment, short-course and drug-resistance programs, alongside other strategies, including the development of newer diagnostics and drugs, is mandatory. © 2009 Expert Reviews Ltd. | en_US |
dc.language | eng | en_US |
dc.publisher | Expert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/loi/ecp | en_US |
dc.relation.ispartof | Expert Review of Clinical Pharmacology | en_US |
dc.subject | Drug Resistant | en_US |
dc.subject | Fluoroquinolone | en_US |
dc.subject | New Drugs | en_US |
dc.subject | Treatment | en_US |
dc.subject | Tuberculosis | en_US |
dc.title | Treatment of multidrug-resistant and extensively drug-resistant tuberculosis: Current status and future prospects | en_US |
dc.type | Article | en_US |
dc.identifier.email | Yuen, KY:kyyuen@hkucc.hku.hk | en_US |
dc.identifier.authority | Yuen, KY=rp00366 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1586/ecp.09.19 | en_US |
dc.identifier.scopus | eid_2-s2.0-70249140575 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-70249140575&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 2 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.spage | 405 | en_US |
dc.identifier.epage | 421 | en_US |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Tam, CM=7201442997 | en_US |
dc.identifier.scopusauthorid | Yew, WW=7005934631 | en_US |
dc.identifier.scopusauthorid | Yuen, KY=36078079100 | en_US |
dc.identifier.issnl | 1751-2433 | - |